BRIEF-Lexicon Pharmaceuticals Provides An Update On The Sotagliflozin Type 2 Diabetes Program

0
45
Shared Hosting - from $2.88/mo

March 19 (Reuters) – Lexicon Pharmaceuticals Inc:

* LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM

* LEXICON PHARMACEUTICALS – TO CLOSE OUT EARLY TWO LONG-TERM OUTCOMES STUDIES OF SOTAGLIFLOZIN, SCORED & SOLOIST

* LEXICON – DECISION TO CLOSE OUT STUDIES EARLY BASED ON ASSESSMENT THAT NEAR-TERM PARTNERSHIP SUFFICIENT TO FUND STUDIES TO COMPLETION IS NOW UNLIKELY

* LEXICON – DECISION TO CLOSE OUT STUDIES EARLY ALSO BASED ON UNCERTAINTIES RELATING TO EFFECTS OF COVID-19 PANDEMIC

* LEXICON PHARMACEUTICALS – WILL PROVIDE FURTHER INFORMATION REGARDING CLOSE-OUT OF STUDIES ON Q1 RESULTS CONFERENCE CALL IN EARLY MAY Source text for Eikon: Further company coverage:

Source link

Shared Hosting - from $2.88/mo

LEAVE A REPLY

Please enter your comment!
Please enter your name here